8 Cheapest Ways to Get Wegovy Right Now (2026)

What's the actual cheapest way to get Wegovy right now?

It splits into two completely different answers depending on one fact: does your insurance cover Wegovy at all. If it does, the manufacturer's savings card makes every other option on this page irrelevant. If it doesn't — because you're uninsured, your plan excludes obesity medication, or you were denied — the cheapest real path runs through Novo Nordisk's own self-pay program, not a mystery coupon site.

The number that gets quoted constantly, over $1,300 a month, is the list price. It exists mainly as a starting point for insurance negotiations. Almost nobody pays it, and after this page, you shouldn't either.

Have insurance? The $25 savings card beats every self-pay option below

The NovoCare Commercial Copay Savings Offer caps your out-of-pocket at $25 a month, provided your commercial insurance covers Wegovy at all — even partially. It doesn't matter what your plan's stated copay is; the manufacturer subsidy absorbs the difference. It cannot be combined with Medicare, Medicaid, or any government insurance, which is standard for manufacturer programs under federal anti-kickback rules.

• Qualifying for it requires two things: your plan covers Wegovy (usually with prior authorization), and you enroll at novocare.com or at the pharmacy counter.
• If you were denied, that's a separate problem from the savings card itself — an appeal with a physician letter documenting BMI and comorbidities reverses a meaningful share of first-round denials.
• The card applies per fill, and terms can shift, so confirm the current cap directly with NovoCare before assuming $25 is locked in indefinitely.

For the full mechanics of getting your plan to cover Wegovy in the first place, see Wegovy savings programs.

No insurance or a denial: NovoCare's self-pay tablet is the new price floor

This is the part that's actually changed recently. Novo Nordisk's own self-pay program, not a third-party discount, is now the lowest verified price for brand-name Wegovy — and it applies identically whether you have zero insurance or you have a plan that simply won't cover this drug. There's no separate, marked-up tier for a denial.

The tablet, approved in December 2025 as the first oral GLP-1 for weight management, starts at $149 a month — the lowest brand-name figure on this page, with a step up at higher doses. The pen carries its own introductory rate for new patients before settling to its standard price at maintenance dosing.

One caveat worth carrying with you: NovoCare is the pharmacy and pricing layer, not the medical visit. You still need a prescriber, whether that's your own doctor or a telehealth intake. For the full breakdown of every no-insurance pathway side by side, see Wegovy without insurance.

GoodRx vs. NovoCare direct: is the coupon actually cheaper anymore?

For years, GoodRx and the manufacturer's own price were two separate things, and GoodRx sometimes won. That's changed for Wegovy specifically. Since January 2026, GoodRx has partnered with Novo Nordisk to surface the manufacturer's own cash price directly, at more than 70,000 pharmacies nationwide — the same $149-a-month tablet, the same stepped pen pricing. GoodRx isn't discounting Wegovy independently anymore; it's a second front door into the identical NovoCare program.

Here's the trap: if you pull up a GoodRx coupon for Wegovy and see something closer to $1,200 or $1,400, that's the old-style retail coupon at a pharmacy outside the cash-price partnership, not this program. The gap between those two GoodRx numbers is enormous, so it's worth confirming which one you're looking at rather than assuming any GoodRx price is automatically the good one. Practically, this makes the choice between NovoCare and GoodRx mostly about convenience — mail order from NovoCare, or pickup at a local pharmacy through GoodRx — rather than price.

Compounded semaglutide: cheaper than brand, but is it the same drug?

Below NovoCare's self-pay price sits compounded semaglutide: the same active molecule, prepared by a licensed 503A pharmacy for an individual patient rather than manufactured and FDA-approved as a finished drug. It is not Wegovy, legally or regulatorily, even though it works on the same receptor. Three providers currently offer verified, transparent pricing on it.

Fridays — cheapest if you commit to a year

Fridays' annual plan brings the price to roughly $150 a month, bundling in dietitian access, group coaching, and messaging support. Month-to-month runs closer to $249. The honest caveat: the annual rate requires prepaying upfront, and Fridays' BBB profile shows a recurring pattern of complaints about refund difficulty for anyone who needs to exit early. Read our Fridays review before prepaying a year.

Mochi Health — flat pricing, ABOM-certified physicians

Mochi splits the bill into $99 a month for the medication and $79 a month for membership, landing around $178 all-in. That price doesn't rise as you titrate up, and Mochi requires its physicians to hold obesity-medicine board certification — a real differentiator if that clinical specialization matters to you. More detail in our Mochi Health review.

Henry Meds — one flat number, oral or injectable

Henry Meds bundles the medication, visits, and shipping into a single all-in price: $249 a month oral, $297 a month injection, with no membership fee stacked on top and no increase as your dose climbs. See the Henry Meds review for the full picture, including what's not included, like lab work.

The regulatory ground under all three has narrowed since 2025 and is still moving: broad compounding tied to the old drug-shortage exemption ended once semaglutide came off the FDA's shortage list, and as of this writing the FDA has proposed — but not finalized — removing semaglutide from a separate bulk-compounding list used by larger outsourcing facilities. What remains clearly legal is a 503A pharmacy compounding for a named patient under a valid prescription, which is the model each of these three operates under.

Ranked: the cheapest Wegovy options this month, lowest to highest

Pulling everything above into one list, ordered by realistic monthly cost rather than a teaser rate:

• 1. NovoCare savings card, if your insurance covers Wegovy: $25/mo
• 2. NovoCare self-pay tablet, or GoodRx mirroring the same price: from $149/mo
• 3. Fridays, on the annual plan: ~$150/mo
• 4. Mochi Health, all-in: ~$178/mo
• 5. Henry Meds, all-in: $249–$297/mo
• 6. NovoCare self-pay pen, at its ongoing (non-intro) rate: $349–$399/mo
• 7. Retail pharmacy with no program at all: ~$1,349/mo

Notice the pen's $199 introductory rate doesn't appear as its own line — it's temporary, and the honest comparison is against the rate you'll actually be paying most months, not the first two fills.

Costco, Walmart, and other retail-cash prices — do they actually beat the manufacturer?

Not meaningfully, and that's worth knowing before you assume a warehouse club has a secret discount. Costco members can access Wegovy through its Member Prescription Program at $349 a month for standard doses, with a $199-a-month introductory rate on the two lowest doses for new patients — numbers that land right in line with NovoCare's own pen pricing, not below it. Walmart and other chains generally sell at the same manufacturer-set self-pay price when a program applies, or at the full retail list price when it doesn't.

The practical takeaway: once Novo Nordisk's own cash price is available broadly through NovoCare and GoodRx, no retail pharmacy is quietly underpricing the manufacturer. Shop for convenience — which pharmacy is nearby, whether you want mail order — rather than expecting one storefront to beat another on the drug itself.

Will Wegovy get cheaper? What's realistically coming

Not from patent expiration, not soon. Semaglutide's core composition patent is starting to lapse in some countries this year, but the method-of-use patents covering its weight-management approval extend into the early 2030s, and realistic US biosimilar competition for the injectable is generally projected toward the early-to-mid 2030s rather than 2026 or 2027. A generic version of Rybelsus, an older, lower-dose oral semaglutide approved only for diabetes, is targeted around 2027 by at least one manufacturer — but that's a different product from the Wegovy tablet, not a substitute for it.

The more realistic pressure on price is coming from Novo Nordisk itself: the self-pay program, the GoodRx partnership, and Costco's discount arrangement all represent the manufacturer competing on cash price rather than waiting for a generic to force its hand. The other variable to watch is the FDA's pending decision on bulk compounding for semaglutide — if it finalizes as proposed, the compounded options on this page could tighten in supply, which would push more cost-conscious patients back toward NovoCare's own self-pay numbers rather than away from them.

Red flags: prices that look cheaper than they really are

The more attention GLP-1 drugs get, the more sites try to profit from confusion between the real thing and a look-alike. A few markers separate a legitimate cheap price from a trap.

• No licensed clinician actually reviewing your history — just a questionnaire that auto-generates a prescription.
• An injectable priced well under NovoCare's own $149-$399 range, with no explanation of how that's possible.
• No named, verifiable, US-licensed pharmacy behind the product.
• Marketing language like "generic Wegovy" or "FDA-approved compound" — neither description is accurate for any compounded product on the market.
• Payment requested before any medical review takes place, rather than after a clinician confirms you're a candidate.
• An annual prepay with a refund policy you haven't actually read — ask directly what happens if you need to stop at month four.

What a full year actually costs, by path

• NovoCare savings card ($25/mo): $300/year — the floor, if you're eligible.
• NovoCare tablet or GoodRx at $149/mo: about $1,788/year.
• Fridays on the annual plan (~$150/mo): about $1,800/year; month-to-month (~$249/mo): about $2,988/year.
• Mochi Health (~$178/mo): about $2,136/year.
• Henry Meds oral ($249/mo): about $2,988/year; injection ($297/mo): about $3,564/year.
• NovoCare pen at the standard $349/mo maintenance rate: about $4,188/year; at the HD $399/mo rate: about $4,788/year.
• Retail, no program (~$1,349/mo): about $16,188/year — the number every path above exists to help you avoid.

For the fuller breakdown of how each of these pathways works, including insurance appeals and Medicare's evolving coverage of Wegovy, see Wegovy cost, every pathway explained and the best places to get real Wegovy online.